Detalle Publicación

Progression-free survival (PFS) and second PFS (PFS2) by disease stage in patients (pts) with homologous recombination deficiency (HRD)-positive newly diagnosed advanced ovarian cancer receiving bevacizumab (bev) with olaparib/placebo maintenance in the phase III PAOLA-1/ENGOT-ov25 trial.

Autores: Pautier, P.; Harter, P.; Pisano, C.; Cropet, C.; Hernando Polo, S.; Berger, R.; Matsumoto, T.; Vergote, I.; Colombo, N.; Noettrup, T. J.; Garnier, G.; Hillemanns, P.; Zamagni, C.; González Martín, Antonio; Lefeuvre-Plesse, C.; Denschlag, D.; Lortholary, A.; Sehouli, J.; Selle, F.; Ray-Coquard, I. L.
Título de la revista: JOURNAL OF CLINICAL ONCOLOGY
ISSN: 0732-183X
Volumen: 39
Número: 15 (Supplement)
Fecha de publicación: 2021
Impacto: